EP
APLS

Eversept Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Eversept Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-126,400
Closed -$4.17M – 110
2021
Q3 		$4.17M Buy
+126,400
New +$7.1M 0.29% 55

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Eversept Partners's APLS Position: Q4 2023 in Review

Eversept Partners sold out of Apellis Pharmaceuticals (APLS) in Q4 2023, closing a stake of 122,643 shares — an estimated $4.67M sold.

Eversept Partners first reported a position in APLS in Q2 2018 and held it in 15 quarters. The position peaked at $24.1M in Q1 2020. 283 funds tracked by Wall St. Rank hold APLS as of Q4 2023.

  • Eversept Partners reported no remaining Apellis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Eversept Partners sold 122,643 Apellis Pharmaceuticals shares in Q4 2023, an estimated $4.67M.
  • Eversept Partners first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 15 quarters.
  • Eversept Partners's Apellis Pharmaceuticals position peaked at $24.1M in Q1 2020.
  • 283 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2023.

Based on Eversept Partners's 13F filing for Q4 2023, filed 14 Feb 2024.